D
uring acute human immunodeficiency virus (HIV) infection, depletion of CD4 + T cells in the host gut mucosa occurs prior to its occurrence in the peripheral blood and other lymphoid tissues. Expression of integrin α4β7, a gut-homing receptor on CD4 + T cells, not only provides a potential receptor for HIV but also plays a critical role in lymphocyte migration from the circulation to the intestine. In our previous study, it was found that circulating guthoming α4β7 CD4 + T cells, including the Th17 and Th1 subsets, were significantly depleted during acute HIV-1 infection. 1 Moreover, no gut-homing Treg cells were depleted. Thus, the gut-homing Treg:Th17 ratio was inversely correlated with the CD4 T + cell count.
Recently, there has been increased interest in the changes in gut-homing CD4 + T cells during HIV infection. Girard et al. 2 found that when treating HIV+ patients with suppressive antiretroviral therapy (ART), immunological non-responders exhibited a significantly higher rate of gut-homing α4β7 CD4 + T cells compared to immunological responders. Kelley et al. 3 also found that expression of integrin α4β7 in a population of black men who have sex with men (MSM) was higher than that in white MSM. In another study by Briceño et al., 4 a depletion of gut-homing CD4 + T cells was also observed in ART-naive patients. These findings provide novel insight into gut-homing CD4 + T cells and their subsets in HIV-infected patients, as well as Th1/Treg and Th17/ Treg imbalances.
Notably, Briceño et al. 4 found that the gut-homing CD4 + T-cell count increased after initiation ART, although the levels were not restored to the normal range. This finding suggests that the immune status of gut-homing CD4 + T cells can be altered in response to ART regimens. Conversely, if integrin α4β7 can be targeted and blocked, it brings into question whether the gp120-α4β7 interaction and lymphocyte homing also change. Byrareddy et al. 5 tested this hypothesis by administering an anti-α4β7 monoclonal antibody to rhesus macaques before and during acute SIV infection. The authors found that the gut-associated lymphoid tissue (GALT) was protected and CD4 + T cells were significantly preserved in both the blood and GALT of rhesus macaques receiving the targeted antibody therapy. Thus, targeting α4β7 could be a potential therapy for HIV/SIV-infected patients, and its efficacy in humans should be explored in future research.
Depletion of gut-homing CD4 + T cells and their subsets mediates HIV progression via different mechanisms. Migration of lymphocytes to the GALT was found to be induced by the interaction of integrin α4β7 and HIV-1 envelope protein gp120. 6 This interaction resulted in rapid activation of LFA-1, an integrin that facilitates HIV-1 infection. Thus, viral dissemination is promoted, and the depletion of gut CD4+ T cells also contributes to HIV-1-induced immune dysfunction. Depletion of Th17 cells was found to be associated with HIV disease progression and viral replication by Salgad et al. 7 This finding could be attributed to the protective role of Th17 cells against bacterial and fungal infections. 8 Since interleukin-17 plays an important role in the integrity of the mucosal barrier, a loss of Th17 cells might result in increased translocation of the gut microbial flora 9 and/or microbial products across the gastrointestinal mucosa without overt bacteremia. 10 In addition, an imbalanced Th17/Treg ratio may lead to progressive disruption of the mucosal barrier, further contributing to microbial translocation across the intestinal mucosa. 9 This translocation may result in activation of antigen-presenting cells in the gastrointestinal mucosa and lymphoid organs by microbial products, which would promote local and systemic inflammation and immune activation.
Understanding the pathological mechanism of HIV infection and disease progression through gut-homing CD4 + T cells and their subsets is of vital importance; however, current studies have primarily focused on gut-homing CD4 + T cells and microbial translocation. Moreover, the data pertaining to the relationship between CD4 + T cells and HIV-related cancer are scarce. Although ART has greatly improved the overall survival of HIV-infected patients, patients continue to face an increased risk of developing a wide range of cancers. This risk is largely associated with the loss of immunity because of depletion of CD4+ T cells by HIV. Many researchers have discovered a remarkable association between a reduced CD4 + T-cell count and several types of cancer, 11 including Kaposi's sarcoma, Non-Hodgkin lymphoma, Hodgkin lymphoma, cervical cancer, anal cancer, and liver cancer. Recently, Helleberg et al. 12 found that among HIV-infected patients with an undetectable viral load, those with a CD4 + T-cell decline greater than 30% had a significantly increased risk of developing cancer (e.g., lung cancer, head and neck tumors, brain tumors, and hepatocellular carcinoma). CD4 + T cells play different roles in anti-tumor immune responses. Th1 cells promote tumor eradication by enhancing macrophage and natural killer recruitment to tumor sites. Moreover, the Th17 subset is involved in the regulation of tumor progression via an unknown mechanism. The Th17 subset primarily secretes IL-17A and IL-17F, 13 of which IL-17A induces specific chemokine expression (for example, CCL2, CCL7, CXCL1, and CCL20) related to the inflammatory response and anti-tumor surveillance. However, IL-17 is also known to induce angiogenesis and cancer cell proliferation, 14 which may be responsible for the cancer-promoting characteristics of the Th17 subset. 15 It is well known that CD4 + Treg cells prevent autoimmune responses and inhibit excessive immune activation. Moreover, these Treg populations also play an important role in anti-tumor immunity. Tregs have also been found to be recruited to tumor microenvironments and inhibit effective anti-tumor immune responses. 14 Taken together, these studies indicate that relationship between gut-homing α4β7 CD4 + T cells and cancer development in AIDS patients remains unknown ( Figure 1 ). Further investigation is required to reveal the status of guthoming α4β7 CD4 + T cells and their subsets in HIV-infected patients, as well as the underlying mechanisms of HIVrelated cancer.
